Glycolipid-Containing Nanoparticle Vaccine Engages Invariant NKT Cells to Enhance Humoral Protection against Systemic Bacterial Infection but Abrogates T-Independent Vaccine Responses.
Shute T, Amiel E, Alam N, Yates JL, Mohrs K, Dudley E, Salas B, Mesa C, Serrata A, Angel D, Vincent BK, Weyers A, Lanthier PA, Vomhof-Dekrey E, Fromme R, Laughlin M, Durham O, Miao J, Shipp D, Linhardt RJ, Nash K, Leadbetter EA.
Shute T, et al. Among authors: lanthier pa.
J Immunol. 2021 Apr 15;206(8):1806-1816. doi: 10.4049/jimmunol.2001283.
J Immunol. 2021.
PMID: 33811104